IP Library Granted Patent US 8,742,083
Granted Patent B1
US 8,742,083 · App. 12/978,086 · Granted Jun 3, 2014

Panel of micrornas that silence the MCL-1 gene and sensitize cancer cells to ABT-263

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,742,083
App. No.
12/978,086
Granted
Jun 3, 2014
Kind
B1
Abstract

MicroRNAs (miRNAs) that sensitize cancer cells to Bcl-2 family protein inhibitors are identified and described. Oligonucleotide panels, arrays and methods using the sensitizing miRNAs are also disclosed.

Claims (11)

1. A panel of primers or probes for determining an miRNA profile in a biological sample, the panel comprising:

at least two miRNA primers or probes, each primer or probe capable of selectively binding one of at least two human miRNA selected from SEQ ID NOS: 1-19; and

a solid support, wherein the primers or probes are probes immobilized on the solid support to form an array.

2. A panel of primers or probes according to claim 1 , wherein the solid support comprises one or more components selected from the group consisting of: a membrane, a chip, a disk, a strip, a filter, a microsphere, a slide, a multiwell plate, a bead, or an optical fiber.

3. A kit useful for assaying miRNA expression levels in a biological sample of a subject, the kit comprising: a) a panel of two or more oligonucleotide primers or probes, each primer or probe capable of selectively binding a human miRNA selected from the group consisting of: SEQ ID NOS: 1-19; b) one or more reagents for amplifying the miRNA present in the biological sample using the primers or probes; and c) instructions for quantifying expression levels of the miRNA in the biological sample and evaluating the sensitivity of the subject to treatment with a Bcl-2 family protein inhibitor based on the expression levels of the miRNA.

4. The kit of claim 3 , wherein the one or more miRNAs are selected from the group consisting of SEQ ID NOS: 1-12.

5. The kit of claim 3 , wherein the one or more miRNAs are selected from the group consisting of SEQ ID NOS: 1-10.

6. The kit of claim 3 further comprising a solid support, wherein the probes or primers comprise probes immobilized on the solid support.

7. The kit of claim 6 , wherein the solid support comprises one or more components selected from the group consisting of: a membrane, a chip, a disk, a strip, a filter, a microsphere, a slide, a multiwell plate, a bead, or an optical fiber.

8. The kit of claim 3 , wherein the biological sample is selected from the group consisting of: a cell lysate, a cell culture, a cell line, a tissue, a biological fluid, a blood sample, a serum sample, a plasma sample, a urine sample, and a skin sample.

9. The kit of claim 3 , wherein the one or more reagents comprise one or more miRNA hybridization or amplification reagents for any two or more of the miRNAs.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030137/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2011
From: SEMIZAROV, DIMITRI; LU, XIN; LAM, LLOYD T.
To: ABBOTT LABORATORIES
Reel/Frame 025973/0177 →